(Q36889127)

16 August 2017

1 reference

title

Potential roles of erythropoietin in the management of anaemia and other complications diabetes (English)

1 reference

16 August 2017

1 reference

Alireza Khoshdel

1

1 reference

16 August 2017

Shane Carney

2

1 reference

16 August 2017

Alastair Gillies

3

1 reference

16 August 2017

Adnan Mourad

4

1 reference

16 August 2017

Bernard Jones

5

1 reference

16 August 2017

Ranjit Nanra

6

1 reference

16 August 2017

Paul Trevillian

7

1 reference

16 August 2017

language of work or name

1 reference

21 July 2007

1 reference

Diabetes, Obesity and Metabolism

16 August 2017

published in

1 reference

16 August 2017

volume

10

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

1-9

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

21 January 2018

Epidemiology of diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00884.X

10.1111/J.1463-1326.2008.00884.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference